NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis → Biden v. ____ _____ in 2024 (From TradeSmith) (Ad) Free BIOS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,600 shsAverage Volume122,781 shsMarket Capitalization$209.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BioPlus Acquisition alerts: Email Address Ad Stansberry ResearchA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead.To get its name and ticker symbol for free - just click here. About BioPlus Acquisition Stock (NASDAQ:BIOS)BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Read More Ad Stansberry ResearchA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead.To get its name and ticker symbol for free - just click here. BIOS Stock News HeadlinesMay 28, 2024 | bizjournals.comMadison's Mirus Bio to be acquired by MilliporeSigma for $600 millionMay 23, 2024 | msn.comBiogen enters deal to acquire HI-Bio for $1.8bnMay 22, 2024 | bizjournals.comBiogen to buy San Francisco startup developing a drug for kidney disease for $1.2BMay 22, 2024 | markets.businessinsider.comBiogen’s Strategic Acquisition of HI-Bio and Diversification into Orphan Drug Market Prompt ‘Buy’ RatingMay 22, 2024 | bizjournals.comBiogen to buy Peninsula startup developing a drug for kidney disease for $1.2 billionMay 22, 2024 | msn.comBiogen buys California biotech for $1.15 billionMay 14, 2024 | markets.businessinsider.comVerde Bio and SensaSure Technologies Complete Merger to Create Premier Mineral Acquisitions CompanyApril 16, 2024 | markets.businessinsider.comImugene and Kincell Bio Announce Strategic Manufacturing and Process Development PartnershipApril 3, 2024 | benzinga.comLouis G Lange's Net WorthFebruary 9, 2024 | msn.comWhy Intelligent Bio Solutions Stock Is Ripping HigherJanuary 22, 2024 | investing.comBioPlus Co Ltd (099430)October 4, 2023 | msn.comSPAC BioPlus, Avertix terminate merger; BioPlus to liquidateOctober 4, 2023 | markets.businessinsider.comAvertix, BIOS Acquisition Agree To Terminate Merger DealOctober 4, 2023 | finance.yahoo.comAvertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business CombinationOctober 4, 2023 | finance.yahoo.comBioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to LiquidateAugust 16, 2023 | finance.yahoo.comHeart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient MonitoringAugust 16, 2023 | finance.yahoo.comAvertix Partners with Institute on Implantable Heart Attack Detection SystemJuly 20, 2023 | finance.yahoo.comAvertix Medical Welcomes Renown Cardiologist to Board of DirectorsJuly 17, 2023 | finance.yahoo.comRenown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of DirectorsJune 13, 2023 | finance.yahoo.comAvertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth OrlandoMay 26, 2023 | seekingalpha.comBIOS BioPlus Acquisition Corp.May 5, 2023 | msn.comSPAC BIOS to merge with cardiac device maker AvertixMay 3, 2023 | finance.yahoo.comAvertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition CorporationMarch 18, 2023 | money.usnews.comBioPlus Acquisition Corp - Ordinary Shares - Class ASeptember 23, 2022 | wsj.comBioPlus Acquisition Corp. Cl ASee More Headlines Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CUSIPN/A CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.20 million OptionableNot Optionable Beta0.01 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jonathan M. N. Rigby MBA (Age 55)Chairman & Chief Bus. Officer Mr. R. Ross Haghighat (Age 59)CEO, CFO & Director Key CompetitorsMontana TechnologiesNASDAQ:AIRJTrinity CapitalNASDAQ:TRINAres Acquisition Co. IINYSE:AACTFusion Acquisition Corp. IINYSE:FSNBCION InvestmentNYSE:CIONView All Competitors BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an initial public offering on Friday, December 3rd 2021. The company issued 18,000,000 shares at a price of $10.00 per share. Cantor served as the underwriter for the IPO. This page (NASDAQ:BIOS) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredBiden v. ____ _____ in 2024Everyone seems focused on Biden getting replaced before election day. But THIS is the real election story n...TradeSmith | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredThe Greatest LEGAL Transfer of Wealth in History is UnderwayWhat's the #1 Stock to Build Generational Wealth RIGHT NOW? One Wall Street millionaire will give you a sur...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPlus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.